Latest Ratios: P/E Ratio -7.5x · EV/EBITDA N/A · ROE -33.5%. (2012–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $718M | $502M | $231M | $218M | $48M | $39M | $66M | $22M | $32M | $59M | $64M |
| Enterprise Value | $664M | $448M | $56M | $198M | $-38036318 | $15M | $59M | $7M | $18M | $41M | $10M |
| P/E Ratio → | -7.49 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | 64.61 | — | — |
| P/B Ratio | 2.21 | 1.57 | 0.95 | 0.98 | 0.39 | 0.97 | 1.85 | 0.63 | 2.74 | 2.01 | 1.26 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | 36.83 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | -5418.8% | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | -5472.8% | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -33.5% | -33.5% | -31.4% | -30.2% | -239.2% | -97.7% | -74.4% | -110.7% | -133.9% | -90.6% | -64.6% |
| ROA | -31.6% | -31.6% | -30.0% | -28.9% | -222.8% | -83.6% | -65.0% | -90.7% | -94.2% | -69.1% | -81.4% |
| ROIC | -50.3% | -50.3% | -46.2% | -33.7% | -552.3% | -125.2% | -85.1% | -225.4% | -445.9% | -677.6% | — |
| ROCE | -39.4% | -39.4% | -35.7% | -31.1% | -238.7% | -96.2% | -75.5% | -112.5% | -123.8% | -80.5% | -92.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | — | 0.21 | 0.20 | 0.18 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.17 | -0.72 | -0.09 | -0.70 | -0.59 | -0.21 | -0.44 | -1.18 | -0.61 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -263.71 | -58.65 | -42.48 | -32.37 |
Net cash position: cash ($60M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.49 | 17.49 | 21.73 | 25.13 | 24.42 | 7.25 | 7.74 | 9.33 | 2.90 | 4.75 | 8.14 |
| Quick Ratio | 17.49 | 17.49 | 21.73 | 25.13 | 24.42 | 7.25 | 7.74 | 9.33 | 2.90 | 4.75 | 8.14 |
| Cash Ratio | 17.15 | 17.15 | 21.34 | 24.99 | 24.12 | 7.03 | 7.20 | 9.01 | 2.72 | 4.63 | 8.04 |
| Asset Turnover | — | — | — | — | — | — | — | — | 0.03 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $56M | $30M | $15M | $9M | $3M | $2M | $842472 | $361359 | $270503 | $134032 |
Single-asset clinical dependency
As reported in recent financial filings, ATXS trades at a price-to-book ratio of 2.21, a valuation that appears to hinge entirely on the speculative probability of success for STAR-0215 rather than any tangible earnings or revenue-generating assets currently present on the balance sheet.
The lack of meaningful P/E or P/S multiples renders traditional valuation metrics largely irrelevant for this stage of the company's lifecycle. Investors should monitor the P/B ratio relative to peers like Cullinan Therapeutics, as any significant deviation may suggest that the market is either overestimating the clinical potential of the YTE-modified antibody or underpricing the dilution risk inherent in future capital raises.
Based on historical financial data, the company's ROIC has remained deeply negative, reaching -15.5% in 2025Q3, which underscores the substantial capital destruction inherent in funding long-term clinical trials without the benefit of commercialized products to offset the heavy research and development expenditures.
The persistent decay in ROIC suggests that the firm is currently in a value-consuming phase of its lifecycle, where every dollar of invested capital is directed toward regulatory and clinical milestones rather than operational efficiency. Investors should interpret these negative returns as a necessary, albeit risky, cost of attempting to build a competitive moat in the HAE treatment space.
According to the most recent quarterly reports, the company maintains a current ratio of 10.78, which appears deceptively strong but masks the reality that the firm's liquidity is rapidly depleting as it funds the intensive development of its lead candidate, STAR-0215, without any offsetting revenue.
While the high current ratio suggests an ability to meet short-term obligations, the rapid decline from 33.83 in 2024Q1 indicates that the company's cash runway is narrowing significantly. This trend warrants close monitoring, as the firm's reliance on external financing to maintain its liquidity position leaves it highly vulnerable to shifts in capital market sentiment.
As indicated by standard industry analysis, the price-to-earnings ratio is the most commonly misapplied metric for ATXS, as it obscures the company's pre-revenue status and fails to account for the massive, non-recurring R&D investments that characterize the firm's current financial profile.
Investors should instead focus on the cash burn rate and the duration of the cash runway, as these metrics provide a more accurate assessment of the company's survival timeline. Relying on earnings-based multiples in a clinical-stage biotech context may lead to erroneous conclusions regarding the firm's underlying value and its ability to reach commercialization.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ATXS stock.
Astria Therapeutics, Inc.'s current P/E ratio is -7.5x. This places it at the 50th percentile of its historical range.
Astria Therapeutics, Inc.'s return on equity (ROE) is -33.5%. The historical average is -115.6%.
Based on historical data, Astria Therapeutics, Inc. is trading at a P/E of -7.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.